In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.53, indicating a +2.02% shift from the previous trading day.

In the biotech sphere, ARK continued its accumulation of CRISPR Therapeutics AG (NASDAQ:CRSP) by acquiring 37,075 shares worth $1.97 million. This purchase is part of a broader strategy, as ARK has ...

NVIDIA’s most recent 13F filing showed no position in Recursion Pharmaceuticals, indicating a complete exit from its previous ...

Future AI-guided genomic analysis offers the potential to further optimize gene constructs, expression profiles, and performance traits, accelerating the development of next-generation materials.

You don't call RLM tools directly. You ask Claude to analyze large files, and Claude uses RLM behind the scenes. With these in place, Claude will autonomously detect when to use RLM instead of reading ...

According to God of Prompt on Twitter, the implementation of verification loops in AI models—where the system recursively checks its answers using different reasoning modes such as backward ...

Abstract: In this research paper, we present a novel method for obtaining the patterns of inputs that generate low-weight codewords in Recursive Systematic Convolutional (RSC) codes, hereafter ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...